Huma funding news – UK-based Huma Secures $80 Million in Series D Round Funding

The platform offers no-code configuration of regulated disease management tools for any therapeutic area, a library of pre-built modules and device connectivity capabilities, a cloud-agnostic framework for flexible hosting, readily available APIs and integration capabilities, the ability to host and deploy diagnostic and predictive AI algorithms, a marketplace, and more to advance digital-first care and research.

The Series D funding round, alongside investments from leading industry partners since its Series C round, created a total issuance of shares by Huma of over $80m. With this round, it has now raised over $300m. The Series D saw the participation of new and existing strategic and financial investors, including AstraZeneca, Hat Technology Fund 4 by HAT SGR, HV Fund by Hitachi Ventures and Leaps by Bayer and others. HSBC Bank plc acted as advisor to Huma during the fundraise.

Read also - Adam Funding news – Czech-based Adam Secures €3 Million in late Seed Funding

The Huma Cloud Platform is built to serve the company's existing regulated products. In 2023, Huma achieved the landmark milestone of becoming the first and only configurable, disease-agnostic FDA Class II, EU MDR Class IIb and Saudi FDA Class C platform, enabling rapid, code-free configuration with the ability to host AI/ML models. The regulatory status of the Huma Cloud Platform significantly reduces the cost, time, and risks associated with bringing digital health projects to life.

It is now making this platform available to customers which comes with a Software Development Kit (SDK) to enable the accelerated development of similar applications or to embed functionalities into their existing solutions.

Dr Juergen Eckhardt, EVP, Head of Leaps by Bayer and Pharmaceuticals Business, Development & Licensing commented: “We have known Huma for several years and we've been impressed by their remarkable progress. We have seen this first-hand. They have demonstrated strong growth and excellent metrics. With their next-generation AI capabilities and Huma Cloud platform, Huma can partner with pharma companies to deliver efficient digital health solutions to patients focused on predictive and proactive care. Pharmaceutical companies need financially and technically efficient digital solutions to minimise spending on efforts that are duplicative or can't scale. The Huma Cloud Platform enables companies to streamline how they bring digital medicine, companion apps, and data collection capabilities to patients from the R&D phase to post-launch.”

Huma also collaborates with over half of the top 20 pharmaceutical companies globally and has been involved in major national healthcare projects worldwide.
Huma has partnered with Google and others to develop new AI models that could enable its Cloud Platform users to care for many times more patients with less work; for example a feature called “10x Nurse” that significantly reduces administrative tasks and brings automation to the patient review process with a human in the loop.

Dan Vahdat, Founder and CEO of Huma, said, “I am thankful for the support of our new and existing shareholders, helping our vision become a reality, which we are closer to than ever before. We are here to accelerate the adoption of digital and AI across care and research, and we do that by making the building of digital health solutions for care and research easy. We like to think of Huma Cloud Platform much like Shopify but for digital health instead of e-commerce. We believe when digital and AI are scaled, they become affordable for both the poor and the rich. This will help us transition medicine from being reactive to proactive.”

About Huma

‍Huma is a global healthcare AI company on a mission to accelerate the adoption of digital solutions in care and research.

Its award-winning modular platforms are used by more than 3,000 hospitals and clinics, with over 35 million screened users and 4 million registered users in healthcare, and has powered over 800 studies supporting about 1 million participants across research.